|
Efficacy (95% confidence intervals)
|
---|
Benguela
|
Zaire
|
Lunda Sul
|
---|
ASAQa
|
ALa
|
ALa
|
DPb
|
DPb
|
ASAQa
|
---|
Uncorrected
|
Per-protocol Day 28
|
90.4 (81–96)
|
89.4 (80–95)
|
75.3 (65–83)
|
95.6 (88–99)
|
100 (94–100)
|
100 (92–100)
|
Per-protocol Day 42
|
–
|
–
|
–
|
81.9 (72–89)
|
100 (94–100)
|
–
|
Kaplan–Meier estimate Day 28
|
90.3 (84–97)
|
89.6 (83–96)
|
76.0 (68–85)
|
95.5 (91–100)
|
100
|
100
|
Kaplan–Meier estimate Day 42
|
–
|
–
|
–
|
82.5 (75–91)
|
100
|
–
|
PCR-corrected
|
Per-protocol Day 28
|
99.9 (95–100)
|
96.1 (89–99)
|
86.5 (77–92)
|
98.8 (94–99)
|
100 (96–100)
|
100 (94–100)
|
Per-protocol Day 42
|
–
|
–
|
–
|
98.5 (92–99)
|
100 (96–100)
|
–
|
Kaplan–Meier estimate Day 28
|
99.9 (95–100)
|
96.3 (91–100)
|
88.1 (81–95)
|
98.8 (96–100)
|
100
|
100
|
Kaplan–Meier estimate Day 42
|
–
|
–
|
–
|
98.8 (96–100)
|
100
|
–
|
- Per-protocol efficacy defined as proportion adequate clinical and parasitological response (ACPR), Kaplan–Meier estimate calculated from estimate of survival function
-
ASAQ artesunate–amodiaquine, AL artemether–lumefantrine, DP dihydroartemisinin–piperaquine
-
a28-day follow up
-
b42-day follow up